Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension

OBJECTIVES: The primary aim was to demonstrate that moxonidine, given in an experimental sustained release (SR) formulation, had no clinically relevant central nervous system (CNS) effects after 4 weeks of treatment. A clinically relevant CNS effect was predefined as more than 45° s(−1) reduction in...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Kemme, Michiel J B, Post, Jeroen P vd, Schoemaker, Rik C, Straub, Matthias, Cohen, Adam F, van Gerven, Joop M A
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Blackwell Science Inc 2003
Θέματα:
Pharmacodynamics
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1884251/
https://ncbi.nlm.nih.gov/pubmed/12814444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2003.01796.x
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια